Aspira Women's Health (AWH) 10-K 31 Mar 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 18, 2022	Jun. 30, 2021
Document And Entity Information [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Current Fiscal Year End Date	--12-31
Entity File Number	001-34810
Entity Registrant Name	Aspira Women’s Health Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-0595156
Entity Address, Address Line One	12117 Bee Caves Road
Entity Address, Address Line Two	Building III
Entity Address, Address Line Three	Suite 100
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78738
City Area Code
Local Phone Number
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	AWH
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 477,546,462
Entity Common Stock, Shares Outstanding		112,138,741
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Central Index Key	0000926617
Amendment Flag	false
Documents Incorporated by Reference	Certain information from the registrant’s definitive Proxy Statement for its Annual Meeting of Stockholders is incorporated by reference into Part III of this report. The registrant intends to file the Proxy Statement with the Securities and Exchange Commission within 120 days of December 31, 2021.
Auditor Name	BDO USA, LLP
Auditor Location	Austin, Texas
Auditor Firm ID	243

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 37,180	$ 16,631
Accounts receivable	1,027	865
Prepaid expenses and other current assets	1,624	1,077
Inventories	174	30
Total current assets	40,005	18,603
Property and equipment, net	464	583
Right-of-use assets	346	406
Restricted cash	250
Other assets	14	13
Total assets	41,079	19,605
Current liabilities:
Accounts payable	1,501	1,103
Accrued liabilities	5,299	3,618
Current portion of long-term debt	201	645
Short-term debt	779	611
Lease liability	60	23
Total current liabilities	7,840	6,000
Non-current liabilities:
Long-term debt	2,718	3,477
Lease liability	349	409
Total liabilities	10,907	9,886
Commitments and contingencies (Note 6)
Stockholders' equity:
Common stock, par value $0.001 per share, 150,000,000 shares authorized at December 31, 2021 and December 31, 2020; 112,138,741 and 104,619,876 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively	112	105
Additional paid-in capital	501,788	449,680
Accumulated deficit	(471,728)	(440,066)
Total stockholders' equity	30,172	9,719
Total liabilities and stockholders' equity	$ 41,079	$ 19,605

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Consolidated Balance Sheets [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	112,138,741	104,619,876
Common stock, shares outstanding	112,138,741	104,619,876

Consolidated Statements Of Oper

Consolidated Statements Of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Revenue	$ 6,812	$ 4,651
Cost of revenue:
Cost of revenue	3,750	3,415
Gross profit	3,062	1,236
Operating expenses:
Research and development	5,314	2,104
Sales and marketing	17,086	8,843
General and administrative	13,257	8,270
Total operating expenses	35,657	19,217
Loss from operations	(32,595)	(17,981)
Interest income (expense), net	(48)	10
Other income , net	981	66
Net loss	$ (31,662)	$ (17,905)
Net loss per share - basic and diluted	$ (0.28)	$ (0.18)
Weighted average common shares used to compute basic and diluted net loss per common share	111,210,614	100,723,303
Product [Member]
Revenue:
Revenue	$ 6,568	$ 4,543
Cost of revenue:
Cost of revenue	3,016	2,517
Genetics [Member]
Revenue:
Revenue	244	108
Cost of revenue:
Cost of revenue	$ 734	$ 898

Consolidated Statements Of Op_2

Consolidated Statements Of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cost Of Revenue [Member]
Stock-based compensation expense	$ 161	$ 106
Research And Development [Member]
Stock-based compensation expense	311	34
Sales And Marketing [Member]
Stock-based compensation expense	1,132	228
General And Administrative [Member]
Stock-based compensation expense	$ 1,935	$ 1,180

Consolidated Statements Of Chan

Consolidated Statements Of Changes In Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance (in shares) at Dec. 31, 2019	97,286,157
Balance at Dec. 31, 2019	$ 97	$ 430,802	$ (422,161)	$ 8,738
Net loss			(17,905)	$ (17,905)
Common stock issued in conjunction with exercise of stock options (in shares)	1,105,675			1,105,675
Common stock issued in conjunction with exercise of stock options	$ 1	1,636		$ 1,637
Common stock issued for restricted stock awards (in shares)	267,706
Common stock issued for restricted stock awards		182		182
Common stock issued in conjunction with warrant exercises (in shares)	2,810,338
Common stock issued in conjunction with warrant exercises	$ 4	5,056		5,060
Common stock and warrants issued in conjunction with private placement, net of $384 in issuance costs (in shares)	3,150,000
Common stock and warrants issued in conjunction with private placement, net of $384 in issuance costs	$ 3	10,638		10,641
Stock-based compensation expense		1,366		1,366
Balance (in shares) at Dec. 31, 2020	104,619,876
Balance at Dec. 31, 2020	$ 105	449,680	(440,066)	9,719
Net loss			(31,662)	$ (31,662)
Common stock issued in conjunction with exercise of stock options (in shares)	557,566			557,566
Common stock issued in conjunction with exercise of stock options		718		$ 718
Common stock issued in conjunction with public offering, net of issuance costs (in shares)	6,900,000
Common stock issued in conjunction with public offering, net of issuance costs	$ 7	47,851		47,858
Common stock issued for restricted stock awards (in shares)	61,299
Common stock issued for restricted stock awards		455		455
Stock-based compensation expense		3,084		3,084
Balance (in shares) at Dec. 31, 2021	112,138,741
Balance at Dec. 31, 2021	$ 112	$ 501,788	$ (471,728)	$ 30,172

Consolidated Statements Of Ch_2

Consolidated Statements Of Changes In Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	Jul. 20, 2020	Dec. 31, 2020
Payments of Stock Issuance Costs		$ 384
Common Stock [Member] | Private Placement [Member]
Payments of Stock Issuance Costs	$ 384

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (31,662)	$ (17,905)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash lease expense	37	26
Depreciation and amortization	302	265
Stock-based compensation expense	3,539	1,548
Loss on sale and disposal of property and equipment	1	3
Forgiveness of PPP loan	(1,006)
Changes in operating assets and liabilities:
Accounts receivable	(162)	59
Prepaid expenses and other assets	(548)	(319)
Inventories	(144)	(5)
Accounts payable, accrued liabilities and other liabilities	2,248	1,594
Net cash used in operating activities	(27,395)	(14,734)
Cash flows from investing activities:
Purchase of property and equipment	(184)	(490)
Net cash used in investing activities	(184)	(490)
Cash flows from financing activities:
Principal repayment of DECD loan	(198)	(192)
Proceeds from DECD loan		2,000
Proceeds from issuance of common stock from exercise of stock options	718	1,637
Proceeds from PPP loan		1,006
Proceeds from exercise of warrants		5,060
Proceeds from private placement		11,025
Payment of issuance costs for private placement		(384)
Proceeds from public offering	48,235
Payment of offering costs for public offering	(377)
Net cash provided by financing activities	48,378	20,152
Net increase in cash, cash equivalents and restricted cash	20,799	4,928
Cash, cash equivalents and restricted cash, beginning of period	16,631	11,703
Cash, cash equivalents and restricted cash, end of period	37,430	16,631
Reconciliation to Consolidated Balance Sheet:
Cash and cash equivalents	37,180	16,631
Restricted cash	250
Unrestricted and restricted cash and cash equivalents	37,430	16,631
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	$ 77	37
Supplemental disclosure of noncash investing and financing activities:
Net (decrease) increase in right-of-use assets		354
Net changes in accounts payable related to capital expenditures		$ 8

Basis Of Presentation And Signi

Basis Of Presentation And Significant Accounting And Reporting Policies	12 Months Ended
	Dec. 31, 2021
Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Basis Of Presentation And Significant Accounting And Reporting Policies	NOTE 1:Basis of Presentation and Summary of Significant Accounting and Reporting Policies Organization and Basis of Presentation Aspira Women’s Health Inc., formerly known as Vermillion, Inc. (“Aspira,” and together with its wholly-owned subsidiaries, the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company currently markets and sells the following products and related services: (1) OVA1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical and radiological evaluation does not indicate malignancy; (2) OVERA, a second-generation biomarker reflex intended to maintain OVA1’s high sensitivity while improving specificity; (3) OVA1plus, a reflex offering which uses OVA1 as the primary test and OVERA as a confirmation for OVA1 intermediate range results and leverages the strengths of OVA1’s Multivariate Index Assay (“MIA”) sensitivity and OVERA’s (MIA2G) specificity and as a result reduces false elevations by over 40%; (4) Aspira GenetiX, a genetic test for hereditary gynecologic cancer risk, with a core focus on hereditary female reproductive cancers, including breast, ovarian, endometrial, uterine and cervical cancers; and (5) Aspira Synergy, a decentralized testing platform and cloud service for decentralized global access of both protein biomarker and hereditary genetic testing. Through December 31, 2021, the Company’s product and related services revenue has been limited to revenue generated by sales of OVA1, OVA1plus and Aspira GenetiX. Liquidity The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $471,728,000, as of December 31, 2021. The Company also expects to incur a net loss and negative cash flows from operations for 2022. In the event that the Company’s existing cash on hand is not sufficient to fund operations, meet its capital requirements or satisfy the anticipated obligations as they become due, the Company expects to take further action to protect its liquidity position. Such actions may include, but are not limited to:Raising capital through an equity offering either in the public markets or via a private placement offering (however, no assurance can be given that capital will be available on acceptable terms, or at all);Reducing executive bonuses or replacing cash compensation with equity grants;Reducing professional services and consulting fees and eliminating non-critical projects;Reducing travel and entertainment expenses; andReducing, eliminating or deferring discretionary marketing programs. In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China. The novel coronavirus has since spread to over 100 countries, including every state in the United States. In March 2020, the World Health Organization declared COVID-19, the disease caused by the novel coronavirus, a pandemic, and the United States declared a national emergency with respect to the coronavirus outbreak. This outbreak has severely impacted global economic activity, and many countries and many states in the United States have reacted to the outbreak by instituting quarantines, mandating business and school closures and restricting travel. In addition, many conventions and industry conferences have been canceled. As a result of the COVID-19 pandemic and actions taken to contain it, the Company’s test volume, and resulting revenue, decreased significantly through the beginning of the third quarter of 2020. Volumes started trending back to pre-COVID levels during the late third quarter of 2020. However, as various COVID-19 variants evolved, the Company experienced fluctuating testing volumes. In order to reduce the impact of limitations on visiting physician offices due to closures and quarantines, the Company implemented other mechanisms for reaching physicians such as virtual sales representative meetings, Key Opinion Leader presentations, and increased digital sales and marketing. Enrollment for clinical research studies has been slower than originally planned due to the impact of clinic closures and patients not seeking medical care in some states. The full impact of the COVID-19 pandemic continues to evolve as of the date these financial statements are first filed with the SEC. As a result, the Company is unable to estimate the extent of the impact of the COVID-19 pandemic on its operations or liquidity. Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company’s equity awards, income taxes and contingent liabilities. Actual results could differ from those estimates. Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation with no material effect on the consolidated financial statements. On the consolidated balance sheet, short-term debt of $400,000 was reclassified to long-term debt. Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes. Highly liquid investments that are considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper. Restricted Cash Restricted cash consists of a security deposit for a financing arrangement. Fair Value Measurement Accounting Standards Codification (“ASC”) Topic 820, Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. ‎ Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of $250,000, but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities. Accounts Receivable Virtually all accounts receivable are derived from sales made to customers located in North America. The Company performs ongoing credit evaluations of its customers’ financial condition and generally does not require collateral. The Company maintains an allowance for doubtful accounts based upon the expected collectability of accounts receivable. Inventory The Company has inventory consisting primarily of kit inventory for specimen delivery as well as reagents used for specimen testing and miscellaneous inventory such as pipettes, gloves and other non-reagent items. At each reporting period the Company reviews its inventories for obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realized value, which is primarily related to kit inventory when kits expire. Inventory is valued at cost. Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized. Revenue Recognition Product Revenue – OVA1, OVERA and OVA1plus: The Company recognizes product revenue in accordance with the provisions of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Product revenue is recognized upon completion of the OVA1, OVERA or OVA1plus test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year. The effect of any change made to an estimated input component and, therefore revenue recognized, would be recorded as a change in estimate at the time of the change. The Company also reviews its patient account population and determines an appropriate distribution of patient accounts by payer (i.e., Medicare, patient pay, other third-party payer, etc.) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. During the years ended December 31, 2021 and 2020, there were no adjustments to estimates of variable consideration to derecognize revenue for services provided in a prior period. There were no impairment losses on accounts receivable recorded during the years ended December 31, 2021 and 2020. Genetics Revenue – Aspira GenetiX: Under ASC 606, the Company’s genetics revenue is recognized upon completion of the Aspira GenetiX test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the Company has limited experience with such factors relating to Aspira GenetiX. Research and Development Costs Research and development costs are expensed as incurred. Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on behalf of the Company. In addition, acquisitions of assets to be consumed in research and development, with no alternative future use, are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established. Patent Costs Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within general and administrative expenses on the Consolidated Statements of Operations. Such costs aggregated to approximately $202,000 and $322,000 for the years ended December 31, 2021 and 2020, respectively. Stock-Based Compensation The Company records the fair value of non-cash stock-based compensation costs for stock options related to the 2019 Stock Incentive Plan (“2019 Plan”). The Company estimates the fair value of stock options using a Black-Scholes option valuation model. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. The Company uses the straight-line method to amortize the fair value over the requisite service period of the award, which is generally equal to the vesting period. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment. The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding. This data includes employees’ expected exercise and post-vesting employment termination behaviors. The expected stock price volatility is estimated using Company historical volatility in deriving the expected volatility assumption. The Company made an assessment that Company historic volatility is most representative of future stock price trends. The expected dividend yield is based on the estimated annual dividends that are expected to be paid over the expected life of the options as a percentage of the market value of the Company’s common stock as of the grant date. The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date. The Company records stock-based compensation net of estimated forfeitures. Contingencies The Company accounts for contingencies in accordance with ASC 450 Contingencies (“ASC 450”) which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Management believes that the Company’s accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized. ASC Topic 740, Accounting for Uncertainty in Income Taxes clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure. The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets. Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalent shares outstanding during the period. Common stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share. Fair Value of Financial Instruments Financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities and debt. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments. The carrying amount of restricted cash represents a long-term security deposit for a financial arrangement that is at cost. The carrying value of debt approximates fair value due to its interest rate approximating market rates of interest available to the Company for similar instruments. Segment Reporting The Company’s chief operating decision maker evaluates the business on a consolidated basis and therefore, the Company operates one operating and reportable segment.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2021
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	NOTE 2:Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update changes the impairment model from the currently used incurred loss methodology to an expected loss methodology, which will result in the more timely recognition of losses. The ASU is scheduled to be effective in 2023 for smaller reporting companies. The Company is currently assessing the impact of this ASU on its consolidated financial statements.

Strategic Alliance With Quest D

Strategic Alliance With Quest Diagnostics Incorporated	12 Months Ended
	Dec. 31, 2021
Strategic Alliance With Quest Diagnostics Incorporated [Abstract]
Strategic Alliance With Quest Diagnostics Incorporated	NOTE 3:Strategic Alliance with Quest Diagnostics Incorporated In March 2015, the Company reached an agreement with Quest Diagnostics Incorporated (“Quest Diagnostics”). Pursuant to this agreement, all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to Aspira’s wholly-owned subsidiary, ASPiRA LABS, as of August 2015. Pursuant to this agreement, as amended as of March 11, 2020, Quest Diagnostics has continued to provide blood draw and logistics support by transporting specimens to ASPiRA LABS for testing in exchange for a market value fee. The purpose of the 2020 amendment was to extend the term of the Testing and Services Agreement from March 11, 2019 to March 11, 2023 and for the Company to pay an annual fee of $75,000 for the services of a part-time Quest Diagnostics project manager.

Property And Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2021
Property And Equipment [Abstract]
Property And Equipment	Note 4: Property and Equipment The components of property and equipment as of December 31, 2021 and 2020 were as follows: December 31,(in thousands) 2021 2020Machinery and equipment $ 1,094 $ 1,094Demonstration equipment 8 17Computer equipment and software 1,252 1,194Furniture and fixtures 174 154Leasehold improvements 721 701Gross property and equipment 3,249 3,160Accumulated depreciation and amortization (2,785) (2,577)Property and equipment, net $ 464 $ 583 Depreciation expense for property and equipment was $302,000 and $265,000 for the years ended December 31, 2021 and 2020, respectively.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2021
Accrued Liabilities [Abstract]
Accrued Liabilities	NOTE 5:Accrued Liabilities The components of accrued liabilities as of December 31, 2021 and 2020 were as follows: December 31,(in thousands)2021 2020Payroll and benefits related expenses $ 2,652 $ 1,874Collaboration and research agreements expenses 382 616Professional services 1,992 803Other accrued liabilities 273 325Total accrued liabilities $ 5,299 $ 3,618

Commitments, Contingencies And

Commitments, Contingencies And Debt	12 Months Ended
	Dec. 31, 2021
Commitments, Contingencies And Debt [Abstract]
Commitments, Contingencies And Debt	NOTE 6:Commitments, Contingencies and debt Long-term debt consisted of the following: December 31, 2021 2020(in thousands) DECD loan, net of issuance costs$ 2,919 $ 3,116PPP Loan - 1,006Total debt 2,919 4,122Less: Current portion, net of issuance costs (201) (645)Total long-term debt, net of issuance costs$ 2,718 $ 3,477 Coronavirus Aid, Relief, and Economic Security (CARES) Act and Paycheck Protection Program Loan On May 1, 2020, the Company obtained the PPP Loan from BBVA USA in the aggregate amount of approximately $1,006,000. The application for these funds required the Company to, in good faith, certify that the described economic uncertainty at the time made the loan request necessary to support the ongoing operations of the Company. This certification further required the Company to consider its current business activity and its ability to access other sources of liquidity sufficient to support ongoing operations in a manner that was not significantly detrimental to the business. Under the terms of the CARES Act and the PPP, all or a portion of the principal amount of the PPP Loan was subject to forgiveness so long as, over the 24-week period following the Company’s receipt of the proceeds of the PPP Loan, the Company used those proceeds for payroll costs, rent, utility costs or the maintenance of employee and compensation levels. The PPP Loan, which was granted pursuant to a promissory note, was set to mature on May 1, 2022. The Company applied for forgiveness of the PPP Loan in March 2021, and, effective May 27, 2021, the SBA confirmed the waiver of the Company’s repayment of the PPP Loan. The Company recognized a gain on forgiveness of debt of approximately $1,006,000, which is included in other income in the condensed consolidated statements of operations and reduced long- and short-term indebtedness by the same amount. The Company remains subject to an audit of the PPP Loan. There is no assurance that the Company will not be required to repay all or a portion of the PPP Loan as a result of the audit. Loan Agreement On March 22, 2016, the Company entered into a loan agreement (as amended, the “DECD Loan Agreement”) with the DECD, pursuant to which the Company may borrow up to $4,000,000 from the DECD. The loan bears interest at a fixed rate of 2.0% per annum and requires equal monthly payments of principal and interest until maturity, which occurs on April 15, 2026. As security for the loan, the Company has granted the DECD a blanket security interest in the Company’s personal and intellectual property. The DECD’s security interest in the Company’s intellectual property may be subordinated to a qualified institutional lender.  The loan may be prepaid at any time without premium or penalty. An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the DECD Loan Agreement. On December 3, 2020, the Company received a disbursement of the remaining $2,000,000 under the DECD Loan Agreement, as the Company had achieved the target employment milestone necessary to receive an additional $1,000,000 under the DECD Loan Agreement and the DECD determined to fund the remaining $1,000,000 under the DECD Loan Agreement after concluding that the required revenue target would likely have been achieved in the first quarter of 2020 in the absence of the impacts of COVID-19. Under the terms of the DECD Loan Agreement, the Company may be eligible for forgiveness of up to $1,500,000 of the principal amount of the loan if the Company achieves certain job creation and retention milestones by December 31, 2022. Conversely, if the Company is either unable to retain 25 full-time employees with a specified average annual salary for a consecutive two-year period or does not maintain the Company’s Connecticut operations through March 22, 2026, the DECD may require early repayment of a portion or all of the loan plus a penalty of 5% of the total funded loan. As of December 31, 2021, the annual amounts of future minimum principal payments due under the Company’s contractual obligation are shown in the table below. Unamortized debt issuance costs for the DECD loan were $15,000. Debt related to the insurance promissory note of $779,000, as described below, is not included in the following table due to the insurance promissory note being cancelable. Payments Due by Period(in thousands) Total 2022 2023 2024 2025 2026 ThereafterDECD Loan $ 2,933 $ 204 $ 406 $ 452 $ 461 $ 341 $ 1,069Total $ 2,933 $ 204 $ 406 $ 452 $ 461 $ 341 $ 1,069 Insurance Notes During 2021 and 2020, the Company entered into insurance promissory notes for the payment of insurance premiums at an interest rate of 3.74% and 3.88% respectively, with an aggregate principal amount outstanding of approximately $779,000 and $611,000 as of December 31, 2021 and 2020, respectively. The amount outstanding in 2021 could be substantially offset by the cancellation of the related insurance coverage which is classified in prepaid insurance. These notes are payable in ten monthly installments with maturity dates of October 1, 2022 and October 1, 2021, respectively. Operating Leases The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease. The Company’s principal facility, including the CLIA laboratory used by ASPiRA LABS, is located in Austin, Texas, and the CLIA laboratory used for research and development services is located in Trumbull, Connecticut. In October 2021, the Company renewed the Austin, Texas lease for one additional year. The Company’s renewed lease expires on January 31, 2023, with no automatic renewal or renewal option. The Company’s Texas lease has a term of  12 months, and the Company has elected the policy of not recording leases on the balance sheet when the leases have terms of 12 months or less. The Company recognized the lease payments in profit and loss on a straight-line basis over the term of the lease, and variable lease payments in the period in which the obligation for the payments was incurred. In October 2015, the Company entered into a lease agreement for a facility in Trumbull, Connecticut. The lease required initial payments for the buildout of leasehold improvements to the office space, which were approximately $596,000. In September 2020, the Company exercised the renewal option for its Trumbull, Connecticut lease. The Company’s renewed lease expires on June 30, 2026, with a five year renewal option. The Company is not reasonably certain that it will exercise the five-year renewal option beginning on July 1, 2026. The expense associated with these operating leases for the years ended December 31, 2021 and 2020 is shown in the table below (in thousands), of which $108,000 and $53,000 related to rent and variable costs, respectively, for the Texas lease.  Twelve Months Ended December, 31Lease CostClassification2021 2020Operating rent expense Cost of revenue$ 59 $ 54 Research and development 44 38 Sales and marketing 33 26 General and administrative 68 57Variable rent expense Cost of revenue$ 32 $ 26 Research and development 32 16 Sales and marketing 37 45 General and administrative 61 61 Based on the Company’s leases as of December 31, 2021, the table below sets forth the approximate future lease payments related to operating leases with initial terms of one year or more (in thousands). 2022$95 2023 106 2024 116 2025 124 2026 64 Total Operating Lease Payments 505 Less: Interest (96) Present Value of Lease Liabilities$409 Weighted-average lease term and discount rate were as follows: Weighted-average remaining lease term (in years) 4.5 Weighted-average discount rate 9.33% Non-cancelable Collaboration Obligations and Other Commitments The Company is a party to an amended research collaboration agreement with The Johns Hopkins University School of Medicine under which the Company licenses certain of its intellectual property directed at the discovery and validation of biomarkers in human subjects, including but not limited to clinical application of biomarkers in the understanding, diagnosis and management of human disease. Under the terms of the amended research collaboration agreement, Aspira is required to pay the greater of 4% royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $57,500. Royalty expense for the years ended December 31, 2021 and 2020 totaled $263,000 and $181,000, respectively, as recorded in cost of revenue in the condensed consolidated statements of operations. Contingent Liabilities From time to time, the Company is involved in legal proceedings and regulatory proceedings arising from operations. The Company establishes reserves for specific liabilities in connection with legal actions that management deems to be probable and estimable. The Company is not currently a party to any proceeding, the adverse outcome of which would have a material adverse effect on the Company’s financial position or results of operations.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2021
Common Stock [Abstract]
Common Stock	NOTE 7:Common Stock 2020 Exercise of Warrants On February 17, 2017, the Company issued certain warrants to purchase up to an aggregate of 2,810,338 shares of Aspira common stock at an exercise price of $1.80 per share in connection with a February 2017 private placement of Aspira common stock. The warrants were initially sold at a price of $0.125 per share of common stock underlying the warrants.  On June 1, 2020, following the 20th consecutive trading day for which the closing price per share of Aspira common stock, as reported on the Nasdaq stock market, exceeded the exercise price, the Company sent notice to the investors holding such warrants accelerating the expiration date of the warrants, in accordance with the terms thereof. Pursuant to the terms of the warrants, any portion of the warrants not exercised prior to such accelerated expiration date would become void and of no value. As of June 9, 2020, all of the warrants were exercised.  The Company issued 2,810,338 shares of Aspira common stock and received $5,060,000 in aggregate proceeds from the exercise of the warrants. As of the date of the issuance of these financial statements, there are no outstanding warrants for the purchase of Aspira common stock. 2020 Private Placement On July 20, 2020, the Company completed a private placement pursuant to which certain investors purchased 3,150,000 shares of Aspira common stock at a price of $3.50 per share. Net proceeds of the private placement were $10,641,000, after deducting expenses related to the private placement of $384,000. The sale of common stock qualified for equity treatment under GAAP. 2021 Public Offering On February 4, 2021, the Company entered into an underwriting agreement (the “2021 Underwriting Agreement”) with William Blair & Company, L.L.C. and Truist Securities, Inc., as representatives of several underwriters (the “2021 Underwriters”), in connection with the underwritten public offering of 6,000,000 shares of Aspira common stock at a price to the public of $7.50 per share. The 2021 Underwriters purchased these 6,000,000 shares at the public offering price per share, less the underwriting discount of $0.4875 per share. Under the 2021 Underwriting Agreement, the Company granted the 2021 Underwriters an option to purchase up to an additional 900,000 shares of Aspira common stock at the public offering price, less the underwriting discount of $0.4875 per share.  On February 5, 2021, the 2021 Underwriters notified the Company that they were exercising this option in connection with the closing of the 2021 Offering. The 2021 Offering, including the additional 900,000 shares of Aspira common stock, closed on February 8, 2021 and resulted in net proceeds to the Company of approximately $47,858,000, after deducting underwriting discounts and offering expenses of $377,000.

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2021
Loss Per Share [Abstract]
Loss Per Share	NOTE 8: Loss Per Share The reconciliation of the numerators and denominators of basic and diluted loss per share for the years ended December 31, 2021 and 2020 was as follows: Loss Shares Per Share(In thousands, except shares and per share data)(Numerator) (Denominator) Amount Year ended December 31, 2021: Net loss - basic $ (31,662) 111,210,614 $ (0.28)Dilutive effect of common stock shares issuable upon exercise of stock options - - Net loss - diluted $ (31,662) 111,210,614 $ (0.28) Year ended December 31, 2020: Net loss - basic $ (17,905) 100,723,303 $ (0.18)Dilutive effect of common stock shares issuable upon exercise of stock options - - Net loss - diluted $ (17,905) 100,723,303 $ (0.18) Due to net losses for the years ended December 31, 2021 and 2020, diluted loss per share is calculated using the weighted average number of common shares outstanding and excludes the effects of potential shares of common stock that are antidilutive. The potential shares of common stock that have been excluded from the diluted loss per share calculation above for the years ended December 31, 2021 and 2020 were as follows: Year Ended December 31, 2021 2020Stock options 10,257,908 8,212,112Potential common shares 10,257,908 8,212,112

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2021
Employee Benefit Plans [Abstract]
Employee Benefit Plans	NOTE 9:Employee Benefit Plans 2010 Stock Incentive Plan The Company’s employees, directors, and consultants were eligible to receive awards under the Vermillion, Inc. Second Amended and Restated 2010 Stock Incentive Plan, which was replaced by the 2019 Plan (as defined below) with respect to future equity grants. As of December 31, 2021, a total of 4,366,311 shares of Aspira common stock were reserved for issuance with respect to outstanding stock options. 2019 Stock Incentive Plan At the Company’s 2019 annual meeting of stockholders, the Company’s stockholders approved the Vermillion, Inc. 2019 Stock Incentive Plan (the “2019 Plan”). The purposes of the 2019 Plan are (i) to align the interests of the Company’s stockholders and recipients of awards under the 2019 Plan by increasing the proprietary interest of such recipients in the Company’s growth and success; (ii) to advance the interests of the Company by attracting and retaining non-employee directors, officers, other employees, consultants, independent contractors and agents; and (iii) to motivate such persons to act in the long-term best interests of the Company and its stockholders. The 2019 Plan allows the Company to grant stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to participants. Subject to the terms and conditions of the 2019 Plan, the initial number of shares authorized for grants under the 2019 Plan is 10,492,283. To the extent an equity award granted under the 2019 Plan expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares of common stock subject to such award will become available for future grant under the 2019 Plan. As of December 31, 2021, there were 3,729,204 shares of Aspira common stock available for future grants under the 2019 Plan. As of December 31, 2021, there were 5,891,597 shares of Aspira common stock subject to outstanding stock options and there were no outstanding restricted stock units. The activity related to shares available for grant under the 2010 Plan and the 2019 Plan for the years ended December 31, 2021 and 2020 was as follows: 2010 Stock Option Plan 2019 Stock Option Plan Total Shares available at December 31, 2019 670,400 10,285,283 10,955,683Options canceled 718,500 502,000 1,220,500Options granted - (3,925,409) (3,925,409)Restricted stock units granted - (356,940) (356,940)Shares forfeited (1,388,900) - (1,388,900)Shares available at December 31, 2020 - 6,504,934 6,504,934 Options canceled 95,626 1,321,646 1,417,272Options granted - (4,020,634) (4,020,634)Restricted stock units granted - (76,742) (76,742)Shares forfeited (95,626) - (95,626)Shares available at December 31, 2021 - 3,729,204 3,729,204 The stock option activity under the 2010 Plan and the 2019 Plan for the years ended December 31, 2021 and 2020 was as follows: Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term Options outstanding at December 31, 2019 6,612,878 $ 1.67 $ 303,995 8.66Granted 3,925,409 1.46 Exercised (1,105,675) 1.48 Canceled (1,220,500) 0.75 Options outstanding at December 31, 2020 8,212,112 $ 1.49 $ 42,833,712 7.51Granted 4,020,634 6.22 Exercised (557,566) 1.29 Canceled (1,417,272) 4.34 Options outstanding at December 31, 2021 10,257,908 $ 2.96 $ 3,797,181 7.44 Shares exercisable: December 31, 2021 4,773,394 $ 1.61 $ 2,182,917 5.91Shares expected to vest: December 31, 2021 5,484,514 $ 4.14 $ 1,614,267 7.77 The range of exercise prices for options outstanding and exercisable at December 31, 2021 is as follows: Exercise Price Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Life in Years Options Exercisable Weighted Average Exercise Price $ 0.47-$ 1.11 3,079,820 $0.78 7.49 1,723,473 $0.80 1.23- 2.05 2,623,941 1.53 5.64 2,027,441 1.57 2.08- 7.40 4,348,147 5.14 8.41 984,980 2.86 7.79- 7.79 206,000 7.79 9.07 37,500 7.79 $ 0.47-$ 7.79 10,257,908 $ 2.96 7.44 4,773,394 $ 1.61 (in thousands) Total Intrinsic Value of Options Exercised Total Fair Value of Vested OptionsYear ended December 31, 2021$ 2,903 $ 4,325Year ended December 31, 2020$ 3,439 $ 3,254 Stock-based Compensation Stock-based Compensation Expense The Company records stock-based compensation net of estimated forfeitures. The assumptions used to calculate the fair value of options granted under the 2010 Plan and the 2019 Plan that were incorporated in the Black-Scholes pricing model for the years ended December 31, 2021 and 2020 were as follows: Year Ended December 31, 2021 2020Dividend yield -% -%Volatility 89% 84%Risk-free interest rate 0.63% 0.71%Expected lives (years) 3.8 2.9 Weighted average grant date fair value$ 3.94 $ 0.87 The allocation of employee and director stock-based compensation expense by functional area for the years ended December 31, 2021 and 2020 was as follows: Twelve Months Ended December 31,(in thousands) 2021 2020Cost of revenue $ 153 $ 96Research and development 350 33Sales and marketing 1,210 162General and administrative 1,658 924Total $ 3,371 $ 1,215 As of December 31, 2021, total unrecognized compensation cost related to unvested stock option awards was approximately $12,110,000 and the related weighted average period over which it is expected to be recognized was 3.14 years. As of December 31, 2021, there was no unrecognized compensation costs related to restricted stock units. 401(k) Plan The Company’s 401(k) Plan allows eligible employees to defer up to an annual limit of the lesser of 90.0% of eligible compensation or a maximum contribution amount subject to the Internal Revenue Service annual contribution limit. The Company is not required to make Company contributions under the 401(k) Plan. During the years ended December 31, 2021 and 2020, the Company did not make Company contributions to the 401(k) Plan.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Taxes [Abstract]
Income Taxes	NOTE 10:Income Taxes There was no current income tax expense or benefit for the years ended December 31, 2021 or 2020 because of net losses during those years. These net losses were generated from domestic operations. Domestic and foreign components of loss from continuing operations before income taxes for the years ended December 31, 2021 and 2020 were $31,662,000 and $17,905,000, respectively. Based on the available objective evidence, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets at December 31, 2021 and 2020. Therefore there was no deferred income tax expense or benefit for the years ended December 31, 2021 or 2020. The components of net deferred tax assets (liabilities) at December 31, 2021 and 2020 were as follows: Year Ended December 31,(in thousands)2021 2020Deferred tax assets: Net operating losses$ 38,268 $ 32,740Amortization - R&D intangibles 2,404 1,873Depreciation and amortization 633 622Other 587 -Total deferred tax assets 41,892 35,235Valuation allowance (41,892) (35,195)Deferred tax assets $ - $ 40 Deferred tax liabilities: Other$ - $ 40Deferred tax liabilities$ - $ 40 Net deferred tax asset$ - $ - The reconciliation of the statutory federal income tax rate to the Company’s effective tax rate for the years ended December 31, 2021 and 2020 was as follows: Year Ended December 31, 2021 2020Tax at federal statutory rate 21% 21%State tax, net of federal benefit (2) 1 Valuation allowance (21) (19) Net operating loss and tax credit carryforwards - (2) Permanent items 1 (1) Other 1 - Effective income tax rate -% -% Legislation commonly referred to as the Tax Cuts and Jobs Act (H.R. 1) was enacted on December 22, 2017. As a result of the Tax Cuts and Jobs Act of 2017, federal net operating losses (“NOLs”) arising before January 1, 2018, and federal NOLs arising after January 1, 2018, are subject to different rules. The Company's pre-2018 federal NOLs of $91,000,000, which are not limited from offsetting future taxable income under Section 382, will expire in varying amounts from 2022 through 2037, if not utilized; and can offset 100% of future taxable income for regular tax purposes. The Company’s federal NOLs of $82,000,000 arising after January 1, 2018, can generally be carried forward indefinitely and can offset up to 80% of future taxable income. State NOLs will expire in varying amounts from 2022 through 2037 if not utilized. The Company's ability to use its NOLs during this period will be dependent on the Company's ability to generate taxable income, and the NOLs could expire before the Company generates sufficient taxable income. The Company's ability to use its net operating loss and credit carryforwards to offset future taxable income is restricted due to ownership change limitations that have occurred in the past, as required by Section 382 of the Internal Revenue Code of 1986, as amended (“Section 382”), as well as similar state provisions. Net operating losses which are limited from offsetting any future taxable income under Section 382 are not included in the gross deferred tax assets presented above. The valuation allowance was approximately $41,892,000 and $35,195,000 at December 31, 2021 and 2020, respectively. The increase of approximately $6,700,000 between 2020 and 2021 is primarily due to adjustments to the domestic deferred tax assets related to net operating losses. The Company files income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. The Company has not been audited by the Internal Revenue Service or any state income or franchise tax agency. As of December 31, 2021, the Company's federal returns for the years ended 2018 through the current period and most state returns for the years ended 2017 through the current period are still open to examination. In addition, all of the net operating losses and research and development credits generated in years earlier than 2018 and 2017, respectively, are still subject to Internal Revenue Service audit. The federal and California tax returns for the year ended December 31, 2020 reflect research and development carryforwards of $5,112,000 and $5,396,000, respectively. For the year ended December 31, 2021, the Company anticipates claiming additional research and development credits of $260,000 on its federal tax return and $248,000 on its California tax return. As of December 31, 2021, the Company's gross unrecognized tax benefits are approximately $10,581,000 which are attributable to research and development credits. A reconciliation of the change in the Company's unrecognized tax benefits is as follows: (in thousands) Federal Tax State Tax TotalBalance at December 31, 2019 $ 5,293 $ 5,351 $ 10,644Increase in tax position during 2020 20 45 65Decrease due to expirations during 2020 (192) - (192)Balance at December 31, 2020 $ 5,121 $ 5,396 $ 10,517Return to provision true up (9) - (9)Increase in tax position during 2021 260 248 508Decrease due to expirations during 2021 (435) - (435)Balance at December 31, 2021 $ 4,937 $ 5,644 $ 10,581 The increase for the year ended December 31, 2021 relates to positions taken in the current year, which are substantially offset by the expiration of a portion of the carryforward. The decrease for the year ended December 31, 2020 is related primarily to the expiration of a portion of the carryforward. If the $10,581,000 of unrecognized income tax benefit is recognized, approximately $10,581,000 would impact the effective tax rate in the period in which each of the benefits is recognized. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the consolidated statement of operations and comprehensive loss. The Company has not recorded any interest or penalties as a result of uncertain tax positions as of December 31, 2021 and 2020. Accrued interest and penalties would be included within the related liability in the consolidated balance sheet.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 11:Related Party Transactions In March 2021, the Company entered into a consulting agreement, as amended, with David Schreiber, pursuant to which Mr. Schreiber performed certain consulting services for the Company after his service on the Company’s board of directors had concluded.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	NOTE 12:SUBSEQUENT EVENTS In connection with our Strategic Research Collaboration Agreement for the development and commercialization of a Micro RNA high risk ovarian cancer early-detection test with Harvard Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Medical University of Lodz, during March 2022, the Company exercised the option for an exclusive world-wide license of this cutting-edge miRNA technology and plans to continue development of a novel combined assay utilizing a new platform with the Company’s collaborators. During the first quarter of 2022, the Company executed a reorganization resulting in the separation of a number of employees. The organizational changes will result in the recording of one-time severance, separation, and settlement payments as well as legal costs in the first quarter of approximately $1,258,000 including estimated future payouts, partially offset by insurance reimbursement of $523,000.

Basis Of Presentation And Summa

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies (Policy)	12 Months Ended
	Dec. 31, 2021
Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Organization And Basis of Presentation	Organization and Basis of Presentation Aspira Women’s Health Inc., formerly known as Vermillion, Inc. (“Aspira,” and together with its wholly-owned subsidiaries, the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company currently markets and sells the following products and related services: (1) OVA1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical and radiological evaluation does not indicate malignancy; (2) OVERA, a second-generation biomarker reflex intended to maintain OVA1’s high sensitivity while improving specificity; (3) OVA1plus, a reflex offering which uses OVA1 as the primary test and OVERA as a confirmation for OVA1 intermediate range results and leverages the strengths of OVA1’s Multivariate Index Assay (“MIA”) sensitivity and OVERA’s (MIA2G) specificity and as a result reduces false elevations by over 40%; (4) Aspira GenetiX, a genetic test for hereditary gynecologic cancer risk, with a core focus on hereditary female reproductive cancers, including breast, ovarian, endometrial, uterine and cervical cancers; and (5) Aspira Synergy, a decentralized testing platform and cloud service for decentralized global access of both protein biomarker and hereditary genetic testing. Through December 31, 2021, the Company’s product and related services revenue has been limited to revenue generated by sales of OVA1, OVA1plus and Aspira GenetiX.
Liquidity	Liquidity The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $471,728,000, as of December 31, 2021. The Company also expects to incur a net loss and negative cash flows from operations for 2022. In the event that the Company’s existing cash on hand is not sufficient to fund operations, meet its capital requirements or satisfy the anticipated obligations as they become due, the Company expects to take further action to protect its liquidity position. Such actions may include, but are not limited to:Raising capital through an equity offering either in the public markets or via a private placement offering (however, no assurance can be given that capital will be available on acceptable terms, or at all);Reducing executive bonuses or replacing cash compensation with equity grants;Reducing professional services and consulting fees and eliminating non-critical projects;Reducing travel and entertainment expenses; andReducing, eliminating or deferring discretionary marketing programs. In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China. The novel coronavirus has since spread to over 100 countries, including every state in the United States. In March 2020, the World Health Organization declared COVID-19, the disease caused by the novel coronavirus, a pandemic, and the United States declared a national emergency with respect to the coronavirus outbreak. This outbreak has severely impacted global economic activity, and many countries and many states in the United States have reacted to the outbreak by instituting quarantines, mandating business and school closures and restricting travel. In addition, many conventions and industry conferences have been canceled. As a result of the COVID-19 pandemic and actions taken to contain it, the Company’s test volume, and resulting revenue, decreased significantly through the beginning of the third quarter of 2020. Volumes started trending back to pre-COVID levels during the late third quarter of 2020. However, as various COVID-19 variants evolved, the Company experienced fluctuating testing volumes. In order to reduce the impact of limitations on visiting physician offices due to closures and quarantines, the Company implemented other mechanisms for reaching physicians such as virtual sales representative meetings, Key Opinion Leader presentations, and increased digital sales and marketing. Enrollment for clinical research studies has been slower than originally planned due to the impact of clinic closures and patients not seeking medical care in some states. The full impact of the COVID-19 pandemic continues to evolve as of the date these financial statements are first filed with the SEC. As a result, the Company is unable to estimate the extent of the impact of the COVID-19 pandemic on its operations or liquidity.
Basis Of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated in consolidation
Use Of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company’s equity awards, income taxes and contingent liabilities. Actual results could differ from those estimates.
Reclassification	Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation with no material effect on the consolidated financial statements. On the consolidated balance sheet, short-term debt of $400,000 was reclassified to long-term debt.
Cash And Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes. Highly liquid investments that are considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper.
Restricted Cash	Restricted Cash Restricted cash consists of a security deposit for a financing arrangement.
Fair Value Measurement	Fair Value Measurement Accounting Standards Codification (“ASC”) Topic 820, Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation.
Concentration Of Credit Risk	‎ Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of $250,000, but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities.
Accounts Receivable	Accounts Receivable Virtually all accounts receivable are derived from sales made to customers located in North America. The Company performs ongoing credit evaluations of its customers’ financial condition and generally does not require collateral. The Company maintains an allowance for doubtful accounts based upon the expected collectability of accounts receivable.
Inventory	Inventory The Company has inventory consisting primarily of kit inventory for specimen delivery as well as reagents used for specimen testing and miscellaneous inventory such as pipettes, gloves and other non-reagent items. At each reporting period the Company reviews its inventories for obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realized value, which is primarily related to kit inventory when kits expire. Inventory is valued at cost.
Property And Equipment	Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.
Revenue Recognition	Revenue Recognition Product Revenue – OVA1, OVERA and OVA1plus: The Company recognizes product revenue in accordance with the provisions of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Product revenue is recognized upon completion of the OVA1, OVERA or OVA1plus test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year. The effect of any change made to an estimated input component and, therefore revenue recognized, would be recorded as a change in estimate at the time of the change. The Company also reviews its patient account population and determines an appropriate distribution of patient accounts by payer (i.e., Medicare, patient pay, other third-party payer, etc.) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. During the years ended December 31, 2021 and 2020, there were no adjustments to estimates of variable consideration to derecognize revenue for services provided in a prior period. There were no impairment losses on accounts receivable recorded during the years ended December 31, 2021 and 2020. Genetics Revenue – Aspira GenetiX: Under ASC 606, the Company’s genetics revenue is recognized upon completion of the Aspira GenetiX test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the Company has limited experience with such factors relating to Aspira GenetiX.
Research And Development Costs	Research and Development Costs Research and development costs are expensed as incurred. Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on behalf of the Company. In addition, acquisitions of assets to be consumed in research and development, with no alternative future use, are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established.
Patent Costs	Patent Costs Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within general and administrative expenses on the Consolidated Statements of Operations. Such costs aggregated to approximately $202,000 and $322,000 for the years ended December 31, 2021 and 2020, respectively.
Stock-Based Compensation	Stock-Based Compensation The Company records the fair value of non-cash stock-based compensation costs for stock options related to the 2019 Stock Incentive Plan (“2019 Plan”). The Company estimates the fair value of stock options using a Black-Scholes option valuation model. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. The Company uses the straight-line method to amortize the fair value over the requisite service period of the award, which is generally equal to the vesting period. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment. The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding. This data includes employees’ expected exercise and post-vesting employment termination behaviors. The expected stock price volatility is estimated using Company historical volatility in deriving the expected volatility assumption. The Company made an assessment that Company historic volatility is most representative of future stock price trends. The expected dividend yield is based on the estimated annual dividends that are expected to be paid over the expected life of the options as a percentage of the market value of the Company’s common stock as of the grant date. The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date. The Company records stock-based compensation net of estimated forfeitures.
Contingencies	Contingencies The Company accounts for contingencies in accordance with ASC 450 Contingencies (“ASC 450”) which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Management believes that the Company’s accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized. ASC Topic 740, Accounting for Uncertainty in Income Taxes clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure. The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalent shares outstanding during the period. Common stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share.
Fair Value Of Financial Instruments	Fair Value of Financial Instruments Financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities and debt. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments. The carrying amount of restricted cash represents a long-term security deposit for a financial arrangement that is at cost. The carrying value of debt approximates fair value due to its interest rate approximating market rates of interest available to the Company for similar instruments.
Segment Reporting	Segment Reporting The Company’s chief operating decision maker evaluates the business on a consolidated basis and therefore, the Company operates one operating and reportable segment.

Property And Equipment (Tables)

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property And Equipment [Abstract]
Components Of Property And Equipment	December 31,(in thousands) 2021 2020Machinery and equipment $ 1,094 $ 1,094Demonstration equipment 8 17Computer equipment and software 1,252 1,194Furniture and fixtures 174 154Leasehold improvements 721 701Gross property and equipment 3,249 3,160Accumulated depreciation and amortization (2,785) (2,577)Property and equipment, net $ 464 $ 583

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Accrued Liabilities [Abstract]
Components Of Accrued Liabilities	December 31,(in thousands)2021 2020Payroll and benefits related expenses $ 2,652 $ 1,874Collaboration and research agreements expenses 382 616Professional services 1,992 803Other accrued liabilities 273 325Total accrued liabilities $ 5,299 $ 3,618

Commitments, Contingencies An_2

Commitments, Contingencies And Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments, Contingencies And Debt [Abstract]
Schedule of Long-term Debt	December 31, 2021 2020(in thousands) DECD loan, net of issuance costs$ 2,919 $ 3,116PPP Loan - 1,006Total debt 2,919 4,122Less: Current portion, net of issuance costs (201) (645)Total long-term debt, net of issuance costs$ 2,718 $ 3,477
Annual Amounts of Future Minimum Principal Payments Due Under Certain Contractual Obligations	Payments Due by Period(in thousands) Total 2022 2023 2024 2025 2026 ThereafterDECD Loan $ 2,933 $ 204 $ 406 $ 452 $ 461 $ 341 $ 1,069Total $ 2,933 $ 204 $ 406 $ 452 $ 461 $ 341 $ 1,069
Expense Associated with Operating Leases	Twelve Months Ended December, 31Lease CostClassification2021 2020Operating rent expense Cost of revenue$ 59 $ 54 Research and development 44 38 Sales and marketing 33 26 General and administrative 68 57Variable rent expense Cost of revenue$ 32 $ 26 Research and development 32 16 Sales and marketing 37 45 General and administrative 61 61
Future Lease Payments Related to Operating Leases	2022$95 2023 106 2024 116 2025 124 2026 64 Total Operating Lease Payments 505 Less: Interest (96) Present Value of Lease Liabilities$409 Weighted-average lease term and discount rate were as follows: Weighted-average remaining lease term (in years) 4.5 Weighted-average discount rate 9.33%

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Loss Per Share [Abstract]
Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share	Loss Shares Per Share(In thousands, except shares and per share data)(Numerator) (Denominator) Amount Year ended December 31, 2021: Net loss - basic $ (31,662) 111,210,614 $ (0.28)Dilutive effect of common stock shares issuable upon exercise of stock options - - Net loss - diluted $ (31,662) 111,210,614 $ (0.28) Year ended December 31, 2020: Net loss - basic $ (17,905) 100,723,303 $ (0.18)Dilutive effect of common stock shares issuable upon exercise of stock options - - Net loss - diluted $ (17,905) 100,723,303 $ (0.18)
Potential Shares Of Common Stock Excluded From Diluted Loss Per Share Calculation	Year Ended December 31, 2021 2020Stock options 10,257,908 8,212,112Potential common shares 10,257,908 8,212,112

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Employee Benefit Plans [Abstract]
Activity Related to Shares Available for Grant Under the 2000 Plan and 2010 Plan	2010 Stock Option Plan 2019 Stock Option Plan Total Shares available at December 31, 2019 670,400 10,285,283 10,955,683Options canceled 718,500 502,000 1,220,500Options granted - (3,925,409) (3,925,409)Restricted stock units granted - (356,940) (356,940)Shares forfeited (1,388,900) - (1,388,900)Shares available at December 31, 2020 - 6,504,934 6,504,934 Options canceled 95,626 1,321,646 1,417,272Options granted - (4,020,634) (4,020,634)Restricted stock units granted - (76,742) (76,742)Shares forfeited (95,626) - (95,626)Shares available at December 31, 2021 - 3,729,204 3,729,204
Stock Option Activity Under 2010 Plan and 2019 Plan	Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term Options outstanding at December 31, 2019 6,612,878 $ 1.67 $ 303,995 8.66Granted 3,925,409 1.46 Exercised (1,105,675) 1.48 Canceled (1,220,500) 0.75 Options outstanding at December 31, 2020 8,212,112 $ 1.49 $ 42,833,712 7.51Granted 4,020,634 6.22 Exercised (557,566) 1.29 Canceled (1,417,272) 4.34 Options outstanding at December 31, 2021 10,257,908 $ 2.96 $ 3,797,181 7.44 Shares exercisable: December 31, 2021 4,773,394 $ 1.61 $ 2,182,917 5.91Shares expected to vest: December 31, 2021 5,484,514 $ 4.14 $ 1,614,267 7.77
Range of Exercise Prices for Options Outstanding and Exercisable	Exercise Price Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Life in Years Options Exercisable Weighted Average Exercise Price $ 0.47-$ 1.11 3,079,820 $0.78 7.49 1,723,473 $0.80 1.23- 2.05 2,623,941 1.53 5.64 2,027,441 1.57 2.08- 7.40 4,348,147 5.14 8.41 984,980 2.86 7.79- 7.79 206,000 7.79 9.07 37,500 7.79 $ 0.47-$ 7.79 10,257,908 $ 2.96 7.44 4,773,394 $ 1.61
Fair Value of Options Vested	(in thousands) Total Intrinsic Value of Options Exercised Total Fair Value of Vested OptionsYear ended December 31, 2021$ 2,903 $ 4,325Year ended December 31, 2020$ 3,439 $ 3,254
Assumptions Used to Calculate Fair Value of Options Granted Under 2010 Plan	Year Ended December 31, 2021 2020Dividend yield -% -%Volatility 89% 84%Risk-free interest rate 0.63% 0.71%Expected lives (years) 3.8 2.9 Weighted average grant date fair value$ 3.94 $ 0.87
Allocation of Employee and Director Stock-Based Compensation Expense by Functional Area	Twelve Months Ended December 31,(in thousands) 2021 2020Cost of revenue $ 153 $ 96Research and development 350 33Sales and marketing 1,210 162General and administrative 1,658 924Total $ 3,371 $ 1,215

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Taxes [Abstract]
Components Of Deferred Tax Assets (Liabilities)	Year Ended December 31,(in thousands)2021 2020Deferred tax assets: Net operating losses$ 38,268 $ 32,740Amortization - R&D intangibles 2,404 1,873Depreciation and amortization 633 622Other 587 -Total deferred tax assets 41,892 35,235Valuation allowance (41,892) (35,195)Deferred tax assets $ - $ 40 Deferred tax liabilities: Other$ - $ 40Deferred tax liabilities$ - $ 40 Net deferred tax asset$ - $ -
Reconciliation Of Statutory Federal Income Tax Rate	Year Ended December 31, 2021 2020Tax at federal statutory rate 21% 21%State tax, net of federal benefit (2) 1 Valuation allowance (21) (19) Net operating loss and tax credit carryforwards - (2) Permanent items 1 (1) Other 1 - Effective income tax rate -% -%
Reconciliation Of Change In Unrecognized Tax Benefits	(in thousands) Federal Tax State Tax TotalBalance at December 31, 2019 $ 5,293 $ 5,351 $ 10,644Increase in tax position during 2020 20 45 65Decrease due to expirations during 2020 (192) - (192)Balance at December 31, 2020 $ 5,121 $ 5,396 $ 10,517Return to provision true up (9) - (9)Increase in tax position during 2021 260 248 508Decrease due to expirations during 2021 (435) - (435)Balance at December 31, 2021 $ 4,937 $ 5,644 $ 10,581

Basis Of Presentation And Sum_2

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies (Details) $ in Thousands	Mar. 22, 2016	Dec. 31, 2021USD ($)segment	Dec. 31, 2020USD ($)
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit		$ (471,728)	$ (440,066)
Short-term debt		779	611
Long-term debt		2,919	4,122
Revenue		6,812	4,651
Cost of revenue		3,750	3,415
Patent costs		$ 202	322
Number of reportable segments | segment		1
PPP Loan [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Long-term debt			1,006
Restatement Adjustment [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Short-term debt			(400)
Long-term debt			400
DECD [Member] | DECD Loan Agreement [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Line of credit fixed interest rate	2.00%
Line of credit, maturity date		Apr. 15, 2026
Consecutive period full times employees with specified average annual salary under loan agreement	2 years
Percentage of penalty on total loan fund included in loan agreement	5.00%
Minimum [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life		3 years
Maximum [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life		5 years
Product [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Revenue		$ 6,568	4,543
Cost of revenue		$ 3,016	$ 2,517

Strategic Alliance With Quest_2

Strategic Alliance With Quest Diagnostics Incorporated (Details) $ in Thousands	Mar. 11, 2020USD ($)
Quest Diagnostics [Member] | Amended Agreement [Member]
Line of Credit Facility [Line Items]
Annual fee to services of Part-time Quest Diagnostics project manager	$ 75

Property And Equipment (Narrati

Property And Equipment (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property And Equipment [Abstract]
Depreciation expense for property and equipment	$ 302	$ 265

Property And Equipment (Compone

Property And Equipment (Components Of Property And Equipment) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 3,249	$ 3,160
Accumulated depreciation and amortization	(2,785)	(2,577)
Property and equipment, net	464	583
Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	1,094	1,094
Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	8	17
Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	1,252	1,194
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	174	154
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 721	$ 701

Accrued Liabilities (Components

Accrued Liabilities (Components Of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued Liabilities [Abstract]
Payroll and benefits related expenses	$ 2,652	$ 1,874
Collaboration and research agreements expenses	382	616
Professional services	1,992	803
Other accrued liabilities	273	325
Total accrued liabilities	$ 5,299	$ 3,618

Commitments, Contingencies An_3

Commitments, Contingencies And Debt (Narrative) (Details)	Dec. 03, 2020USD ($)	Apr. 15, 2016USD ($)	Mar. 22, 2016USD ($)employee	Dec. 31, 2021USD ($)item	Dec. 31, 2020USD ($)	Oct. 31, 2015USD ($)
Commitments And Contingencies [Line Items]
Proceeds from development loan					$ 2,000,000
Royalty expense				$ 263,000	181,000
Austin, Texas Facility [Member]
Commitments And Contingencies [Line Items]
Operating lease term				12 months
Lease renewal term				1 year
Lease cost				$ 108,000	$ 53,000
Trumbull, Connecticut Facility [Member]
Commitments And Contingencies [Line Items]
Leasehold improvements						$ 596,000
Lease expiration date				Jun. 30, 2026
Lease renewal term				5 years
DECD Loan Agreement [Member]
Commitments And Contingencies [Line Items]
Unamortized debt issuance costs				$ 15,000
Debt instrument carrying amount				$ 779,000
Insurance Promissory Notes [Member]
Commitments And Contingencies [Line Items]
Debt instrument interest rate				3.74%	3.88%
Aggregate principal amount outstanding				$ 779,000	$ 611,000
Notes payable number of monthly payment installment | item				10
Johns Hopkins University School Of Medicine [Member]
Commitments And Contingencies [Line Items]
Percent of royalty paid				4.00%
Minimum royalty payment				$ 57,500
DECD [Member] | DECD Loan Agreement [Member]
Commitments And Contingencies [Line Items]
DECD maximum borrowing capacity			$ 4,000,000
Line of credit fixed interest rate			2.00%
Line of credit, maturity date				Apr. 15, 2026
Proceeds from development loan	$ 2,000,000	$ 2,000,000
Maximum loan forgiveness amount under loan agreement			$ 1,500,000
Number of full time employees expected to be retained under loan agreement | employee			25
Consecutive period full times employees with specified average annual salary under loan agreement			2 years
Percentage of penalty on total loan fund included in loan agreement			5.00%
DECD [Member] | DECD Loan Agreement [Member] | Loan Agreement Target Employment Milestone [Member]
Commitments And Contingencies [Line Items]
Proceeds from development loan	1,000,000
DECD [Member] | DECD Loan Agreement [Member] | Loan Agreement Required Revenue Target [Member]
Commitments And Contingencies [Line Items]
Proceeds from development loan	$ 1,000,000

Commitments, Contingencies An_4

Commitments, Contingencies And Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Total debt	$ 2,919	$ 4,122
Less: Current portion, net of issuance costs	(201)	(645)
Total long-term debt, net of issuance costs	2,718	3,477
DECD Loan [Member]
Debt Instrument [Line Items]
Total debt	$ 2,919	3,116
PPP Loan [Member]
Debt Instrument [Line Items]
Total debt		$ 1,006

Commitments, Contingencies An_5

Commitments, Contingencies And Debt (Annual Amounts of Future Minimum Principal Payments Due Under Certain Contractual Obligations) (Details) $ in Thousands	Dec. 31, 2021USD ($)
Other Commitments [Line Items]
Contractual obligation, 2022	$ 204
Contractual obligation, 2023	406
Contractual obligation, 2024	452
Contractual obligation, 2025	461
Contractual obligation, 2026	341
Contractual obligation, Thereafter	1,069
Total	2,933
DECD Loan [Member]
Other Commitments [Line Items]
Contractual obligation, 2022	204
Contractual obligation, 2023	406
Contractual obligation, 2024	452
Contractual obligation, 2025	461
Contractual obligation, 2026	341
Contractual obligation, Thereafter	1,069
Total	$ 2,933

Commitments, Contingencies An_6

Commitments, Contingencies And Debt (Expense Associated with Operating Leases) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cost Of Revenue [Member]
Operating rent expense	$ 59	$ 54
Variable rent expense	32	26
Research And Development [Member]
Operating rent expense	44	38
Variable rent expense	32	16
Sales And Marketing [Member]
Operating rent expense	33	26
Variable rent expense	37	45
General And Administrative [Member]
Operating rent expense	68	57
Variable rent expense	$ 61	$ 61

Commitments, Contingencies An_7

Commitments, Contingencies And Debt (Future Lease Payments Related to Operating Leases) (Details) $ in Thousands	Dec. 31, 2021USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2022	$ 95
2023	106
2024	116
2025	124
2026	64
Total Operating Lease Payments	505
Less: Interest	(96)
Present Value of Lease Liabilities	$ 409

Commitments, Contingencies An_8

Commitments, Contingencies And Debt (Weighted-Average Lease Term and Discount Rate) (Details)	Dec. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term (in years)	4 years 6 months
Weighted-average discount rate	9.33%

Common Stock (Details)

Common Stock (Details) - USD ($)	Feb. 08, 2021	Feb. 04, 2021	Jul. 20, 2020	Jun. 09, 2020	Feb. 17, 2017	Dec. 31, 2021	Dec. 31, 2020
Common Stock Equity [Line Items]
Net proceeds after deducting underwriting discounts and offering expenses						$ 48,235,000
Common stock, par value						$ 0.001	$ 0.001
Common stock, shares issued						112,138,741	104,619,876
Costs related to issuance of common stock							$ 384,000
Proceeds from exercise of warrants							5,060,000
Common stock value						$ 112,000	$ 105,000
Common Stock [Member]
Common Stock Equity [Line Items]
Common stock shares issued						6,900,000
2020 Private Placement [Member] | Common Stock [Member]
Common Stock Equity [Line Items]
Common stock shares issued			3,150,000
Common stock share price			$ 3.50
Proceeds from issuance of stock			$ 10,641,000
Private Placement [Member] | Common Stock [Member]
Common Stock Equity [Line Items]
Costs related to issuance of common stock			$ 384,000
2021 Underwriting Agreement [Member]
Common Stock Equity [Line Items]
Costs related to issuance of common stock	$ 377,000
2021 Underwriting Agreement [Member] | Common Stock [Member]
Common Stock Equity [Line Items]
Underwriting agreement, shares		6,000,000
Net proceeds after deducting underwriting discounts and offering expenses	$ 47,858,000
Underwriting commitments additional shares offered	900,000
Common stock shares issued	900,000	6,000,000
Underwriting agreement, per share	$ 0.4875	$ 0.4875
Sale of stock, price per share		$ 7.50
2020 Exercise of Warrants [Member]
Common Stock Equity [Line Items]
Common stock shares issued				2,810,338
Exercise price of warrants					$ 1.80
Stock price per share					$ 0.125
Proceeds from exercise of warrants				$ 5,060,000
Maximum [Member] | 2020 Exercise of Warrants [Member]
Common Stock Equity [Line Items]
Warrants issued to purchase common stock					2,810,338

Loss Per Share (Reconciliation

Loss Per Share (Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Loss (Numerator)
Net loss - basic	$ (31,662)	$ (17,905)
Dilutive effect of common stock shares issuable upon exercise of stock options
Net loss - diluted	$ (31,662)	$ (17,905)
Shares (Denominator)
Net loss - basic	111,210,614	100,723,303
Net loss - diluted	111,210,614	100,723,303
Per Share Amount
Net loss - basic	$ (0.28)	$ (0.18)
Net loss - diluted	$ (0.28)	$ (0.18)

Loss Per Share (Potential Share

Loss Per Share (Potential Shares Of Common Stock Excluded From Diluted Loss Per Share Calculation) (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	10,257,908	8,212,112
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	10,257,908	8,212,112

Employee Benefit Plans (Narrati

Employee Benefit Plans (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	3,729,204	6,504,934	10,955,683
401(k) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
401(k) Plan, percentage for employee maximum contribution amount	90.00%
401(k) employer contributions		$ 0	$ 0
Unvested Stock Option Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation costs related to nonvested stock option awards	$ 12,110,000
Weighted average period over which unrecognized cost expected to be recognized	3 years 1 month 20 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation costs related to nonvested stock option awards	$ 0
2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	3,729,204
Share based compensation shares authorized for grants	10,492,283
Common Stock Subject to Outstanding Stock Options [Member] | 2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	4,366,311
Common Stock Subject to Outstanding Stock Options [Member] | 2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	5,891,597
Common Stock Subject to Outstanding Stock Options [Member] | 2019 Stock Incentive Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	0

Employee Benefit Plans (Activit

Employee Benefit Plans (Activity Related to Shares Available for Grant Under the 2010 Plan and 2019 Plan) (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period	6,504,934	10,955,683
Options canceled	1,417,272	1,220,500
Options. granted	(4,020,634)	(3,925,409)
Restricted stock units granted	(76,742)	(356,940)
Options forfeited	(95,626)	(1,388,900)
Shares available at end of period	3,729,204	6,504,934
2010 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period		670,400
Options canceled	95,626	718,500
Options forfeited	(95,626)	(1,388,900)
2019 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period	6,504,934	10,285,283
Options canceled	1,321,646	502,000
Options. granted	(4,020,634)	(3,925,409)
Restricted stock units granted	(76,742)	(356,940)
Options forfeited
Shares available at end of period	3,729,204	6,504,934

Employee Benefit Plans (Stock O

Employee Benefit Plans (Stock Option Activity Under 2010 Plan and 2019 Plan) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of Shares
Options outstanding	8,212,112	6,612,878
Granted	4,020,634	3,925,409
Exercised	(557,566)	(1,105,675)
Canceled	(1,417,272)	(1,220,500)
Options outstanding	10,257,908	8,212,112	6,612,878
Shares exercisable	4,773,394
Shares expected to vest	5,484,514
Weighted Average Exercise Price
Options outstanding	$ 1.49	$ 1.67
Granted	6.22	1.46
Exercised	1.29	1.48
Canceled	4.34	0.75
Opstions outstanding	2.96	$ 1.49	$ 1.67
Shares exercisable	1.61
Shares expected to vest	$ 4.14
Aggregate Intrinsic Value
Options outstanding	$ 3,797,181	$ 42,833,712	$ 303,995
Shares exercisable	2,182,917
Shares expected to vest	$ 1,614,267
Weighted Average Remaining Contractual Term
Options outstanding	7 years 5 months 8 days	7 years 6 months 3 days	8 years 7 months 28 days
Shares exercisable	5 years 10 months 28 days
Shares expected to vest	7 years 9 months 7 days

Employee Benefit Plans (Range o

Employee Benefit Plans (Range of Exercise Prices for Options Outstanding and Exercisable) (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	$ 0.47
Exercise Price Upper Range	$ 7.79
Options Outstanding | shares	10,257,908
Weighted Average Exercise Price	$ 2.96
Weighted Average Remaining life	7 years 5 months 8 days
Options Exercisable | shares	4,773,394
Weighted Average Exercise Price	$ 1.61
Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	0.47
Exercise Price Upper Range	$ 1.11
Options Outstanding | shares	3,079,820
Weighted Average Exercise Price	$ 0.78
Weighted Average Remaining life	7 years 5 months 26 days
Options Exercisable | shares	1,723,473
Weighted Average Exercise Price	$ 0.80
Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	1.23
Exercise Price Upper Range	$ 2.05
Options Outstanding | shares	2,623,941
Weighted Average Exercise Price	$ 1.53
Weighted Average Remaining life	5 years 7 months 20 days
Options Exercisable | shares	2,027,441
Weighted Average Exercise Price	$ 1.57
Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	2.08
Exercise Price Upper Range	$ 7.40
Options Outstanding | shares	4,348,147
Weighted Average Exercise Price	$ 5.14
Weighted Average Remaining life	8 years 4 months 28 days
Options Exercisable | shares	984,980
Weighted Average Exercise Price	$ 2.86
Range Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	7.79
Exercise Price Upper Range	$ 7.79
Options Outstanding | shares	206,000
Weighted Average Exercise Price	$ 7.79
Weighted Average Remaining life	9 years 25 days
Options Exercisable | shares	37,500
Weighted Average Exercise Price	$ 7.79

Employee Benefit Plans (Fair Va

Employee Benefit Plans (Fair Value of Options Vested) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Employee Benefit Plans [Abstract]
Total Intrinsic Value of Options Exercised	$ 2,903	$ 3,439
Total Fair Value of Vested Options	$ 4,325	$ 3,254

Employee Benefit Plans (Assumpt

Employee Benefit Plans (Assumptions Used to Calculate Fair Value of Options Granted Under 2010 Plan) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Employee Benefit Plans [Abstract]
Dividend yield
Volatility	89.00%	84.00%
Risk-free interest rate	0.63%	0.71%
Expected lives (years)	3 years 9 months 18 days	2 years 10 months 24 days
Weighted average grant date fair value	$ 3.94	$ 0.87

Employee Benefit Plans (Allocat

Employee Benefit Plans (Allocation of Employee and Director Stock-Based Compensation Expense by Functional Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 161	$ 106
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	311	34
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,132	228
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,935	1,180
Employee Stock-based Compensation [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	3,371	1,215
Employee Stock-based Compensation [Member] | Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	153	96
Employee Stock-based Compensation [Member] | Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	350	33
Employee Stock-based Compensation [Member] | Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,210	162
Employee Stock-based Compensation [Member] | General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,658	$ 924

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes [Line Items]
Current income tax expense (benefit)	$ 0	$ 0
Domestic and foreign components of loss from continuing operations before income taxes	31,662,000	17,905,000
Deferred income tax expense (benefit)	0	0
Valuation allowance	41,892,000	35,195,000
Interest and penalties as a result of uncertain tax positions	0	0
Gross unrecognized tax benefits	10,581,000	10,517,000	$ 10,644,000
Prior To 2018 [Member]
Income Taxes [Line Items]
Operating loss carryforwards	91,000,000
2018 And Forward [Member]
Income Taxes [Line Items]
Operating loss carryforwards	82,000,000
Research and Development Credits [Member]
Income Taxes [Line Items]
Operating loss carryforwards	5,112,000	5,396,000
Gross unrecognized tax benefits	10,581,000
Total Unrecognized income tax benefit, affecting effective tax rate if recognized	10,581,000
Federal Tax [Member]
Income Taxes [Line Items]
Increase in valuation allowance	6,700,000
Gross unrecognized tax benefits	$ 4,937,000	$ 5,121,000	$ 5,293,000
Minimum [Member] | Prior To 2018 [Member]
Income Taxes [Line Items]
Operating loss carryforwards expiration date	Dec. 31, 2022
Minimum [Member] | 2018 And Forward [Member]
Income Taxes [Line Items]
Operating loss carryforwards expiration date	Dec. 31, 2022
Maximum [Member] | Prior To 2018 [Member]
Income Taxes [Line Items]
Operating loss carryforwards expiration date	Dec. 31, 2037
Maximum [Member] | 2018 And Forward [Member]
Income Taxes [Line Items]
Operating loss carryforwards expiration date	Dec. 31, 2037
Additional [Member] | Federal Tax [Member] | Research and Development Credits [Member]
Income Taxes [Line Items]
Operating loss carryforwards	$ 260,000
Additional [Member] | California State [Member] | Research and Development Credits [Member]
Income Taxes [Line Items]
Operating loss carryforwards	$ 248,000

Income Taxes (Components Of Def

Income Taxes (Components Of Deferred Tax Assets (Liabilities)) (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating losses	$ 38,268,000	$ 32,740,000
Amortization - R&D intangibles	2,404,000	1,873,000
Depreciation and amortization	633,000	622,000
Other	587,000
Total deferred tax assets	41,892,000	35,235,000
Valuation allowance	(41,892,000)	(35,195,000)
Deferred tax assets		40,000
Deferred tax liabilities:
Other		40,000
Deferred tax liabilities		40,000
Net deferred tax asset

Income Taxes (Reconciliation Of

Income Taxes (Reconciliation Of Statutory Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
Tax at federal statutory rate	21.00%	21.00%
State tax, net of federal benefit	(2.00%)	1.00%
Valuation allowance	(21.00%)	(19.00%)
Net operating loss and tax credit carryforwards		(2.00%)
Permanent items	1.00%	(1.00%)
Other	1.00%
Effective Income Tax Rate Reconciliation, Percent, Total

Income Taxes (Reconciliation _2

Income Taxes (Reconciliation Of Change In Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Contingency [Line Items]
Beginning Balance	$ 10,517	$ 10,644
Return to provision true up	(9)
Increase in tax position	508	65
Decrease due to expirations	(435)	(192)
Ending Balance	10,581	10,517
Federal Tax [Member]
Income Tax Contingency [Line Items]
Beginning Balance	5,121	5,293
Return to provision true up	(9)
Increase in tax position	260	20
Decrease due to expirations	(435)	(192)
Ending Balance	4,937	5,121
State and Local Jurisdiction
Income Tax Contingency [Line Items]
Beginning Balance	5,396	5,351
Return to provision true up
Increase in tax position	248	45
Decrease due to expirations
Ending Balance	$ 5,644	$ 5,396

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Subsequent Event [Line Items]
Restructuring costs	$ 1,258
Insurance reimbursement	$ 523